Severine Vermeire - Selected Publications#

1. Horizon 2020 - Advanced ERC Grant

Reason for selecting: In 2016, SV was awarded an Advanced ERC Grant for the project entitled “Novel diagnostic and therapeutic approach to inflammatory bowel disease based on functional characterization of patients: the CrUCCial index”. This grant meant a confirmation of the scientific value of her work on improving management and outcomes of IBD patients, by bridging and translating basic science findings to the clinic in a personalized way. This represents also the core mission of the IBD group Leuven (www.ibd-kuleuven.com)

2. Seyed Tabib NS, Madgwick M, Sudhakar P, Verstockt B, Korcsmaros T, Vermeire S. Big data in IBD: big progress for clinical practice - . Gut. 2020 Aug;69(8):1520-1532. (impact factor2020 19.819; times cited 1)

3. Alsoud D, Verstockt B, Fiocchi C, Vermeire S. Breaking the therapeutic ceiling in drug development in ulcerative colitis. Lancet Gastroenterol Hepatol. 2021 Jul;6(7):589-595. doi: 10.1016/S2468-1253(21)00065-0

4. Vermeire S, O'Byrne S, Keir M, Williams M, Lu TT, Mansfield JC, Lamb CA, Feagan BG, Panes J, Salas A, Baumgart DC, Schreiber S, Dotan I, Sandborn WJ, Tew GW, Luca D, Tang MT, Diehl L, Eastham-Anderson J, De Hertogh G, Perrier C, Egen JG, Kirby JA, van Assche G, Rutgeerts P. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial - Lancet. 2014 Jul 26;384(9940):309-18. (impact factor2013 39.207; times cited 229)

5. Vermeire S, Lakatos PL, Ritter T, Hanauer S, Bressler B, Khanna R, Isaacs K, Shah S, Kadva A, Tyrrell H, Oh YS, Tole S, Chai A, Pulley J, Eden C, Zhang W, Feagan BG; LAUREL Study Group.Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. Lancet Gastroenterol Hepatol. 2022 Jan;7(1):28-37. doi: 10.1016/S2468-1253(21)00295-8. Epub 2021 Nov 17

6. Vermeire S. Antisense drug for Crohn's disease. Oral SMAD7 N Engl J Med. 2015 Mar 19;372:1166-7. (impact factor2013 54.420; times cited 10)

7. Cleynen I, Van Moerkercke W, Billiet T, Vandecandelaere P, Vande Casteele N, Breynaert C, Ballet V, Ferrante M, Noman M, Assche GV, Rutgeerts P, van den Oord JJ, Gils A, Segaert S, Vermeire S. Characteristics of Skin Lesions Associated With Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease: A Cohort Study - Ann Intern Med. 2016;164:10-22. (impact factor2014 17.810; times cited 53)

8. Vermeire S, Schreiber S, Petryka R et al. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial - Lancet. 2017 Jan 21;389(10066):266-275. (impact factor2017 53.254; times cited 139)

Reason for selecting: This manuscript underlines the active participation in the field of drug development and clinical trials in IBD, and the collaboration with the pharmaceutical industry. Specifically in the case of the development of filgotinib, the collaboration started already for the preclinical studies (in vitro work and mice model), in parallel with the development of the early phase 2A study. S Vermeire is the Head of the International Steering Committee of the phase 3 trial with filgotinib in Crohn’s disease.

9. Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease - Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, Simoens S, Rutgeerts P, Gils, Vermeire S. Gastroenterology. 2015 Jun; 148(7):1320-1329. (impact factor2015 18.187; times cited 395)

Reason for selecting: This was an academic investigator-initiated study conducted in collaboration with the Group of Professor Ann Gils (Pharmabs KU Leuven), and the first randomized trial on proactive therapeutic drug monitoring with biological therapies (in casu anti-TNF) in IBD. The study is conceived internationally as a very important argument for personalized treatment-dosing with anti-TNF.

10. Machiels K, Joossens M, Sabino J, De Preter V, Arijs I, Eeckhaut V, Ballet V, Claes K, Van Immersseel F, Verbeke K, Ferrante M, Verhaegen J, Rutgeerts P, Vermeire S. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis - Gut. 2014;63:1275-1283. (impact factor2014 14.660; times cited 193)

Reasons for selecting: This manuscript was the first basic science publication from the group in the field of the microbiome and IBD. This publication put the research group of S Vermeire on the map in the study of microbial dysbiosis and also lead to future (and still ongoing) collaborations with Jeroen Raes at KU Leuven.